Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

11-08	Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications	CI
11-03	Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026	CI

Market Cap	63.66B 56.82B 52.29B 47.45B 89.93B 5,967B 92.17B 625B 249B 3,195B 239B 234B 10,061B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.27B 66.5B 60.35B 114B 7,589B 117B 796B 317B 4,063B 304B 297B 12,796B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

11-08	Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications	CI
11-03	Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026	CI
10-21	Allergan Aesthetics presents its latest scientific advances
09-29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI
09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news: Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

10-21	Allergan Aesthetics présente ses dernières avancées scientifiques
20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020
Andres Rodrigo BRD	Director/Board Member	-	08/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/8/20 A	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
5/8/20 A	Adriane Brown	Issuer sale	Director	2,916	0.0009%
5/8/20 A	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	+4.28%	+0.07%	+52.75%	+138.78%	1,206B
JOHNSON & JOHNSON	+2.13%	+4.27%	+51.21%	+91.36%	665B
ABBVIE INC.	+0.68%	+1.54%	+33.83%	+112.47%	515B
ROCHE HOLDING AG	+2.77%	+0.98%	+49.44%	+68.46%	381B
MERCK & CO., INC.	+1.38%	+0.27%	+72.42%	+45.30%	362B
NOVARTIS AG	+0.29%	+1.48%	+30.84%	+58.32%	307B
ASTRAZENECA PLC	+0.98%	+1.49%	+9.04%	+34.78%	289B
AMGEN INC.	+1.04%	-0.05%	+45.29%	+76.18%	249B
GILEAD SCIENCES, INC.	+1.46%	-0.59%	+42.48%	+125.82%	207B
Average	+1.54%	+0.50%	+43.03%	+83.50%	424B
Weighted average by Cap.	+2.26%	+0.67%	+45.99%	+96.04%

	2018	2019
Net sales	15.79B 14.09B 12.97B 11.77B 22.3B 1,480B 22.86B 155B 61.83B 792B 59.26B 57.99B 2,495B	16.09B 14.36B 13.21B 11.99B 22.73B 1,508B 23.29B 158B 63.01B 807B 60.39B 59.1B 2,543B
Net income	-5.1B -4.55B -4.19B -3.8B -7.2B -478B -7.38B -50.07B -19.96B -256B -19.13B -18.72B -805B	-5.27B -4.7B -4.33B -3.93B -7.45B -494B -7.63B -51.79B -20.64B -265B -19.78B -19.36B -833B
Net Debt	21.89B 19.54B 17.98B 16.32B 30.93B 2,052B 31.69B 215B 85.73B 1,098B 82.16B 80.41B 3,460B	17.3B 15.45B 14.21B 12.9B 24.45B 1,622B 25.05B 170B 67.77B 868B 64.95B 63.56B 2,735B